Heartland Advisors Inc. acquired a new position in shares of Royalty Pharma PLC (NASDAQ: RPRX) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 96,553 shares of the biopharmaceutical company's stock, valued at approximately $3,406,000. Several other institutional investors and hedge funds also
Royalty Pharma delivered robust FY25 results, with double-digit growth in Royalty Receipts and Portfolio Receipts, and disciplined capital deployment. RPRX expanded its portfolio through $2.6B in new royalty transactions, $1.2B in share repurchases, and a 7% dividend increase entering 2026. Synthetic royalties emerged as a major growth engine, surpassing traditional royalties in announced transaction value and offering structural advantages for biopharma funding.
Royalty Pharma (NASDAQ: RPRX) executives highlighted what they described as a "landmark year" in 2025, pointing to double-digit top-line growth, continued capital deployment into new royalty deals, and a significant strategic change with the internalization of the company's external manager. Management also laid out 2026 guidance that calls for mid-single-digit growth in recurring royalty receipts while
Royalty Pharma delivered robust 2025 results, with Q4 receipts up 17% to $856 million and full-year portfolio receipts at $3.25 billion. The company deployed $2.6 billion into 9 new royalties and repurchased $1.2 billion in shares, reflecting disciplined capital allocation and shareholder focus. Even factoring patent expiries and a more conservative growth outlook, valuation remains attractive, supported by sector momentum and sustained capital returns.
Royalty Pharma plc (RPRX) Q4 2025 Earnings Call Transcript
While the top- and bottom-line numbers for Royalty Pharma (RPRX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Portfolio Rece ipts of $874 million in Q4 2025 and $3,254 million for FY 2025 Portfolio Receipts growth of 18% in Q4 2025 and 16% for FY 2025 Net cas h provided by operating activities of $827 million in Q4 2025 and $2,490 million for FY 2025 Full year 2026 guidance: Portfolio Receipts expected to be $3,275 million to $3,425 million NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the fourth quarter and full year 2025 and introduced full year 2026 guidance for Portfolio Receipts. “We had one of the most remarkable years in Royalty Pharma's history in 2025,” said Pablo Legorreta, Royalty Pharma's Chief Executive Officer and Chairman of the Board.
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Royalty Pharma (RPRX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.
Royalty Pharma PLC (NASDAQ: RPRX - Get Free Report) CFO Terrance Coyne sold 114,954 shares of the stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $42.84, for a total value of $4,924,629.36. Following the sale, the chief financial officer owned 23,972 shares in the company,
Royalty Pharma PLC (NASDAQ: RPRX - Get Free Report) CFO Terrance Coyne sold 108,424 shares of the stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $42.08, for a total transaction of $4,562,481.92. Following the sale, the chief financial officer owned 30,167 shares of the company's stock, valued
